Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • P1068: RISK-ADJUSTED SAFETY AN...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
P1068: RISK-ADJUSTED SAFETY ANALYSIS OF PACRITINIB IN PATIENTS WITH MYELOFIBROSIS

P1068: RISK-ADJUSTED SAFETY ANALYSIS OF PACRITINIB IN PATIENTS WITH MYELOFIBROSIS

Bibliographic Details
Main Authors: A. Vannucchi, N. Pemmaraju, B. Scott, M. Savona, S. Oh, F. Palandri, H. K. Al-Ali, M. Sobas, M. F. McMullin, V. Gupta, A. Yacoub, R. Mesa, S. Buckley, K. Roman-Torres, S. Verstovsek, C. Harrison
Format: Article
Language:English
Published: Wiley 2022-06-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/01.HS9.0000847140.81310.7b
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://journals.lww.com/10.1097/01.HS9.0000847140.81310.7b

Similar Items

  • Risk‐adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis
    by: Naveen Pemmaraju, et al.
    Published: (2022-11-01)
  • P1069: RETROSPECTIVE COMPARISON OF PATIENT OUTCOMES ON PACRITINIB VERSUS RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND THROMBOCYTOPENIA
    by: C. Harrison, et al.
    Published: (2022-06-01)
  • Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
    by: Srdan Verstovsek, et al.
    Published: (2021-09-01)
  • <i>Erratum</i> to: Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
    by: Srdan Verstovsek, et al.
    Published: (2024-04-01)
  • P1057: INDIRECT TREATMENT COMPARISONS OF MOMELOTINIB VS PACRITINIB SAFETY AND ANEMIA OUTCOMES IN PATIENTS WITH MYELOFIBROSIS
    by: Lucia Masarova, et al.
    Published: (2023-08-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs